Aripiprazole lauroxil

• CAT Number: I002767
• CAS Number: 1259305-29-7
• Molecular Formula: C36H51Cl2N3O4
• Molecular Weight: 660.72
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: [7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl dodecanoate
• InChI: InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3
• InChIKey: DDINXHAORAAYAD-UHFFFAOYSA-N
• SMILES: CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl

Aripiprazole lauroxil (Cat.No:I002767), aslo known as RDC 3317, is a long-acting injectable atypical antipsychotic. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to six weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. FDA on 5 October 2015.

Reference

1:Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L.J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691. PMID: 28350572 Free PMC Article2:Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Potkin SG, Risinger R, Du Y, Zummo J, Bose A, Silverman B, Stankovic S, Ehrich E.Schizophr Res. 2017 Mar 22. pii: S0920-9964(17)30124-X. doi: 10.1016/j.schres.2017.03.003. [Epub ahead of print] PMID: 28342578 3:Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia. Raedler LA.Am Health Drug Benefits. 2016 Mar;9(Spec Feature):40-3. No abstract available. PMID: 27668044 Free PMC Article4:Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia. Cruz MP.P T. 2016 Sep;41(9):556-9. PMID: 27630522 Free PMC Article5:Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. Nasrallah HA, Newcomer JW, Risinger R, Du Y, Zummo J, Bose A, Stankovic S, Silverman BL, Ehrich EW.J Clin Psychiatry. 2016 Nov;77(11):1519-1525. doi: 10.4088/JCP.15m10467. PMID: 27574838 Free Article6:Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. Aggarwal A, Gopalakrishna G, Lauriello J.Clin Schizophr Relat Psychoses. 2016 spring;10(1):58-63. doi: 10.3371/csrp.AGGA.040316. Review. PMID: 27074333 7:Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Citrome L.Expert Rev Clin Pharmacol. 2016;9(2):169-86. doi: 10.1586/17512433.2016.1121809. Epub 2015 Dec 19. Review. PMID: 26573020 8:Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW.Int Clin Psychopharmacol. 2016 Mar;31(2):69-75. doi: 10.1097/YIC.0000000000000106. PMID: 26517202 9:A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW.J Clin Psychiatry. 2015 Aug;76(8):1085-90. doi: 10.4088/JCP.14m09741. PMID: 26114240 Free Article10:Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW.Schizophr Res. 2014 Nov;159(2-3):404-10. doi: 10.1016/j.schres.2014.09.021. Epub 2014 Sep 27. PMID: 25266547